The hypoxic triggered mechanism in cancer is similar in function to hypoxia activated prodrugs (HAPs), meaning drugs that are activated in low-oxygen conditions. In contrast, RRx-001’s 2-stage mechanism, with utility under normal conditions coupled with the hypoxia triggered activity, is what places it apart in a class of its own and supports potential benefit across many therapeutic indications.
RRx-001 initial mechanism
Regulating chronic inflammation
The neuroprotective effects of RRx-001
With funding from The Michael J. Fox Foundation for Parkinson’s Research and Shake it Up Australia, we’re exploring how RRx-001’s inhibition of the inflammasome may reduce or reverse symptoms of Parkinson’s and other neurodegenerative diseases. Led by Dr. Richard Gordon at The University of Queensland in Brisbane, Australia, this collaboration studies how RRx-001 binds to cysteines found in immune and red blood cells, promoting protective cellular responses through induction of the Nrf2 pathway and inhibition of the NLRP3 inflammasome.
Control inflammation & control the disease
RRx-001 inhibits the inflammasome
RRx-001 in Oncology
In “abnormal” conditions, such as with cancer, RRx-001 generates an alternate mechanism that has shown in preclinical and clinical studies to normalize blood flow in tumors, allowing oxygenation of tumor tissue and modifying the tumor immune environment with reduction in CD47 expression and reprogramming of tumor associated macrophages.
In effect, RRx-001 is normalizing the environment of the abnormal environment of tumors, allowing functional blood flow and oxygenation.
Cancer prefers to control its environment, creating an impenetrable defense supported by growing irregular and poorly functioning vessels that inhibit blood flow. This restricts delivery of therapies and surveillance from the body’s immune system. Therefore, normalizing the environment of tumors makes them susceptible to treatment that may otherwise fail because it was previously unable to penetrate cancerous tissues.